Rearranging the domain order of a diabodybased IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics

mAbs

Volumn 6, Issue 5, 2014, Pages 1243-1254

  Asano, Ryutaro ^a   Shimomura, Ippei ^a   Konno, Shota ^a   Ito, Akiko ^a   Masakari, Yosuke ^a   Orimo, Ryota ^a   Taki, Shintaro ^a   Arai, Kyoko ^a   Ogata, Hiromi ^a   Okada, Mai ^a   Furumoto, Shozo ^b   Onitsuka, Masayoshi ^c   Omasa, Takeshi ^c   Hayashi, Hiroki ^d   Katayose, Yu ^d   Unno, Michiaki ^d   Kudo, Toshio ^a   Umetsu, Mitsuo ^a   Kumagai, Izumi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antibody engineering; Bispecific diabody; Cancer immunotherapy; CD3; Effective domain order; Epidermal growth factor receptor; IgG like bispecific antibody

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CD3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; HEX3 SCDB FC LH BISPECIFIC ANTIBODY; IMMUNOGLOBULIN G2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER RESISTANCE; CONTROLLED STUDY; CROSS LINKING; DRUG HALF LIFE; DRUG STABILITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY;

EID: 84913588010     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.29445     Document Type: Article

References (36)

1. Byrne H, Conroy PJ, Whisstock JC, O'Kennedy RJ. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 2013; 31:621-32; PMID:24094861; http://dx.doi.org/ 10.1016/j.tibtech.2013.08.007
2. Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs 2009; 1:539-47; PMID:20073127; http://dx.doi.org/ 10.4161/mabs.1.6.10015
3. Holliger P, Winter G. Diabodies: small bispecific antibody fragments. Cancer Immunol Immunother 1997; 45:128-30; PMID:9435855; http://dx.doi.org/ 10.1007/s002620050414
4. Stork R, Campigna E, Robert B, M€uller D, Kontermann RE. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem 2009; 284:25612-9; PMID:19628871; http:// dx.doi.org/10.1074/jbc.M109.027078
5. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974-7; PMID:18703743; http://dx.doi.org/ 10.1126/science.1158545
6. Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem 2004; 279:53907-14; PMID:15471859; http://dx.doi.org/10.1074/jbc. M407888200
7. Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, González Trotter DE, Adams GP. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 2005; 65:1471-8; PMID:15735035; http://dx.doi.org/ 10.1158/0008-5472.CAN-04-2008
8. Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, Williams LE, Chatziioannou AF, Gambhir SS, Wu AM. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003; 44:1962-9; PMID:14660722
9. Carter P. Bispecific human IgG by design. J Immunol Methods 2001; 248:7-15; PMID:11223065; http://dx. doi.org/10.1016/S0022-1759(00)00339-2
10. Marvin JS, Zhu Z. Recombinant approaches to IgGlike bispecific antibodies. Acta Pharmacol Sin 2005; 26:649-58; PMID:15916729; http://dx.doi.org/ 10.1111/j.1745-7254.2005.00119.x
11. Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, Huang F, Phan S, Gao S, Doern A, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. MAbs 2009; 1:128-41; PMID:20061822; http://dx.doi.org/10.4161/mabs.1.2.7631
12. Mabry R, Lewis KE, Moore M, McKernan PA, Bukowski TR, Bontadelli K, Brender T, Okada S, Lum K, West J, et al. Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Protein Eng Des Sel 2010; 23:115-27; PMID:20022918; http://dx.doi.org/ 10.1093/protein/gzp073
13. Asano R, Sone Y, Makabe K, Tsumoto K, Hayashi H, Katayose Y, Unno M, Kudo T, Kumagai I. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent. Clin Cancer Res 2006; 12:4036-42; PMID:16818703; http://dx.doi.org/10.1158/1078-0432.CCR-06-0059
14. Asano R, Kawaguchi H, Watanabe Y, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T, Kumagai I. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells. J Immunother 2008; 31:752-61; PMID:18779744; http://dx. doi.org/10.1097/CJI.0b013e3181849071
15. Watanabe Y, Asano R, Arai K, Shimomura I, Ogata H, Kawaguchi H, Hayashi H, Ohtsuka H, Yoshida H, Katayose Y, et al. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody. Oncol Rep 2011; 26:949-55; PMID:21743971
16. Lu D, Jimenez X, Witte L, Zhu Z. The effect of variable domain orientation and arrangement on the anti-gen-binding activity of a recombinant human bispecific diabody. Biochem Biophys Res Commun 2004; 318:507-13; PMID:15120630; http://dx.doi.org/ 10.1016/j.bbrc.2004.04.060
17. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 2006; 43:1129-43; PMID: 16139892; http://dx.doi.org/10.1016/j.molimm.2005. 07.034
18. Asano R, Kumagai T, Nagai K, Taki S, Shimomura I, Arai K, Ogata H, Okada M, Hayasaka F, Sanada H, et al. Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody. Protein Eng Des Sel 2013; 26:359-67; PMID:23468569; http://dx.doi.org/10.1093/protein/gzt009
19. Dong J, Sereno A, Snyder WB, Miller BR, Tamraz S, Doern A, Favis M,WuX, Tran H, Langley E, et al. Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem 2011; 286:4703-17; PMID:21123183; http://dx.doi.org/ 10.1074/jbc.M110.184317
20. Gu J, Yang J, Chang Q, Lu X, Wang J, Chen M, Ghayur T, Gu J. Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-IgTM) proteins with unique activities. PLoS One 2014; 9:e97292; PMID:24824849; http://dx.doi.org/10.1371/journal. pone.0097292
21. McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, Adams GP, Schier R, Marks JD, Weiner LM. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol 2001; 166:6112-7; PMID:11342630; http://dx. doi.org/10.4049/jimmunol.166.10.6112
22. Yates Z, Gunasekaran K, Zhou H, Hu Z, Liu Z, Ketchem RR, Yan B. Histidine residue mediates radi-cal-induced hinge cleavage of human IgG1. J Biol Chem 2010; 285:18662-71; PMID:20304919; http:// dx.doi.org/10.1074/jbc.M110.108597
23. Yan B, Boyd D, Kaschak T, Tsukuda J, Shen A, Lin Y, Chung S, Gupta P, Kamath A, Wong A, et al. Engineering upper hinge improves stability and effector function of a human IgG1. J Biol Chem 2012; 287:5891-7; PMID:22203673; http://dx.doi.org/ 10.1074/jbc.M111.311811
24. Jeong KJ, Jang SH, Velmurugan N. Recombinant antibodies: engineering and production in yeast and bacterial hosts. Biotechnol J 2011; 6:16-27; PMID:21170983; http://dx.doi.org/10.1002/biot.201000381
25. Spiess C, Merchant M, Huang A, Zheng Z, Yang NY, Peng J, Ellerman D, Shatz W, Reilly D, Yansura DG, et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol 2013; 31:753-8; PMID:23831709; http://dx.doi.org/10.1038/nbt.2621
26. Jefferis R. Glycosylation as a strategy to improve anti-body-based therapeutics. Nat Rev Drug Discov 2009; 8:226-34; PMID:19247305; http://dx.doi.org/ 10.1038/nrd2804
27. Simmons LC, Reilly D, Klimowski L, Raju TS, Meng G, Sims P, Hong K, Shields RL, Damico LA, Rancatore P, et al. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods 2002; 263:133-47; PMID:12009210; http://dx.doi.org/ 10.1016/S0022-1759(02)00036-4
28. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290-7; PMID:17934452; http://dx. doi.org/10.1038/nbt1345
29. Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 2011; 317:1255-60; PMID:21419116; http://dx.doi.org/10.1016/j. yexcr.2011.03.010
30. Asano R, Ikoma K, Kawaguchi H, Ishiyama Y, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T, et al. Application of the Fc fusion format to generate tag-free bi-specific diabodies. FEBS J 2010; 277:477-87; PMID:20015073; http://dx.doi.org/ 10.1111/j.1742-4658.2009.07499.x
31. Arakawa F, Kuroki M, Kuwahara M, Senba T, Ozaki H, Matsuoka Y, Misumi Y, Kanda H, Watanabe T. Cloning and sequencing of the VH and V kappa genes of an anti-CD3 monoclonal antibody, and construction of a mouse/human chimeric antibody. J Biochem 1996; 120:657-62; PMID:8902633; http://dx.doi.org/ 10.1093/oxfordjournals.jbchem.a021462
32. Asano R, Ikoma K, Shimomura I, Taki S, Nakanishi T, Umetsu M, Kumagai I. Cytotoxic enhancement of a bispecific diabody by format conversion to tandem sin-gle-chain variable fragment (taFv): the case of the hEx3 diabody. J Biol Chem 2011; 286:1812-8; PMID:21097496; http://dx.doi.org/10.1074/jbc. M110.172957
33. Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T, Fukuhara K, Suzuki T, Matsuno S. Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med 1995; 177:61-71; PMID:8693487; http://dx.doi.org/10.1620/tjem.177.61
34. Asano R, Watanabe Y, Kawaguchi H, Fukazawa H, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T, et al. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells. J Biol Chem 2007; 282:27659-65; PMID:17644522; http://dx.doi.org/10.1074/jbc. M704719200
35. Makabe K, Nakanishi T, Tsumoto K, Tanaka Y, Kondo H, Umetsu M, Sone Y, Asano R, Kumagai I. Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528. J Biol Chem 2008; 283:1156-66; PMID:17947238; http:// dx.doi.org/10.1074/jbc.M706190200
36. Asano R, Ikoma K, Sone Y, Kawaguchi H, Taki S, Hayashi H, Nakanishi T, Umetsu M, Katayose Y, Unno M, et al. Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody. J Biol Chem 2010; 285:20844-9; PMID:20444691; http:// dx.doi.org/10.1074/jbc.M110.120444